Since 2011, when the United States Food and Drug Administration (U.S. FDA) approved ipilimumab (Yervoy®) for malignant melanoma, several immune-checkpoint inhibitors have been granted marketing authorisation. Do you know all the indications? MediPaper made an overview of all the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.
What is new in the treatment of head and neck cancer, including squamous cell head and neck cancer (SCCHN or HNSCC) and nasopharyngeal carcinoma (NPC)? Read our head and neck cancer blog and learn more about the latest advancements in the treatment of SCCHN and NPC.
Nivolumab (OpdivoⓇ) immunotherapy is active in nasopharyngeal carcinoma (NPC). A study published in JCO by Brigette Ma (CUHK) and a team of researchers from Hong Kong, Singapore, and the US showed promising results with nivolumab in NPC. Read more about immunotherapy in NPC.
There is no excerpt because this is a protected post.
The United States Food and Drug Agency (US FDA) require the development of companion diagnostics (CDx). CDx can help to identify patients at risk and guide patient selection. Moreover, it serves as a marker for treatment outcome. Thus enabling physicians to better balance safety with efficacy. The US FDA motivates the development of a CDx in early stages of clinical studies.
Late breaking abstracts at ESMO 2016 with pembrolizumab are largely in lung cancer. Data includes the phase III Keynote-010, the Keynote-024 study, and a study combining ramucirumab with pembrolizumab in NSCLC will be presented. Furthermore, late breaking abstracts will include data of pembrolizumab in urothelial cancer, the KEYNOTE-052 study.